Another study highlights that LDHC expression is upregulated in the responder population among patients with melanoma undergoing treatment with anti–PD-1 therapy, suggesting that LDHC is a potential predictive biomarker of response to immune checkpoint inhibitor therapy (72). This evidence concerns the gene LDHC and melanoma.